MorphoSys Is At BIO Looking To Buy
This article was originally published in The Pink Sheet Daily
Executive Summary
Flush German biotech looks to in-license or acquire clinical stage biologics to even out its pipeline as it edges from fee-for-service to development business model.
You may also be interested in...
MorphoSys Fills Out Pipeline With Xencor Deal
After searching a year and a half for the right compound to complete its proprietary pipeline, German MorphoSys completed a biotech-biotech deal with a simpatico California company.
MorphoSys Fills Out Pipeline With Xencor Deal
After searching a year and a half for the right compound to complete its proprietary pipeline, German MorphoSys completed a biotech-biotech deal with a simpatico California company.
Novartis Deepens Its Commitment To Biologics With MorphoSys Deal Worth Up To $1 Billion
German mAb company’s single-partner plan includes letting deals expire with other pharmas such as Bayer Schering and J&J, as well as upping internal pipeline investments.